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A
r
L
R
A
G
D
a
M
b
c
d
e
f
g
h
i
j
k
l
R
m
a
A
R
R
A
A
K
M
C
C
A
A
s
T
0
hLeukemia Research 38 (2014) 475–483
Contents lists available at ScienceDirect
Leukemia  Research
journa l h om epage: www.elsev ier .com/ locate / leukres
zacitidine  in  CMML:  Matched-pair  analyses  of  daily-life  patients
eveal  modest  effects  on  clinical  course  and  survival
isa  Pleyera,  Ulrich  Germingb, Wolfgang  R.  Sperrc, Werner  Linkeschd,  Sonja  Burgstallere,
einhard  Stauder f,  Michael  Girschikofskyg,  Martin  Schrederh, Michael  Pfeilstocker i,
lois  Langj,  Thamer  Sliwak,  Dietmar  Geissler l,  Konstantin  Schlicka,
udrun  Placher-Sorkoa, Georg  Theilerd, Josef  Thalere, Martina  Mitrovic f,
aniel  Neureiterm, Peter  Valentc,  Richard  Greil a,∗
3rd Medical Department with Hematology and Medical Oncology, Hemostasiology, Rheumatology and Infectiology, Laboratory for Immunological and
olecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Austria
University Hospital, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Department for Internal Medicine and Hematology, University Hospital, Graz, Austria
Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Austria
Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Austria
Department of Medicine I, Center of Hematology and Stem Cell Transplantation, Hemostasis and Medical Oncology, Elisabethinen Hospital Linz, Austria
1st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
IIIrd Medical Department, Hanusch Hospital, Vienna, Austria
Internal Medicine, Hospital Feldkirch, Austria
5th Medical Department with Oncology und Palliative Medicine, Hietzing, Vienna, Austria
Department for Internal Medicine, with Nephrology, Gastroenterology and Hepatology, Hematology and Medical Onkology, Intensive Care Unit, and
heumatology, Klinikum Klagenfurt am Wörtersee, Pörtschach am Wörthersee, Austria
Institute of Pathology, Paracelsus Medical University, Salzburg, Austria
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 22 November 2013
eceived in revised form 7 January 2014
ccepted 8 January 2014
vailable online 18 January 2014
a  b  s  t  r  a  c  t
Recent  data  suggest  that azacitidine  may  be  beneﬁcial  in CMML.  We  report  on 48  CMML-patients  treated
with azacitidine.  Overall  response  rates  were  high  (70%  according  to IWG-criteria,  including  22%  complete
responses).  Monocyte  count  and  cytogenetics  adversely  affected  survival,  whereas  age,  WHO-type,  FAB-
type,  and  spleen  size did  not.  Matched-pair  analyses  revealed  a trend  for higher  two-year-survival  for
azacitidine  as  compared  to  best  supportive  care  (62% vs.  41%, p = 0.067)  and  longer  OS  for azacitidine  ﬁrst-eywords:
atched-pair analysis
MML
hronic myelomonocytic leukemia
zacitidine
ustrian Azacitidine Registry
line  vs.  hydroxyurea  ﬁrst-line  (p =  0.072,  median  OS  27.7  vs.  6.2 months).  This  report  reinforces  existing
evidence  that azacitidine  is  safe  and  efﬁcacious  in  both  myelodysplastic  and  myeloproliferative  CMML.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  Open access under CC BY-NC-ND license. ClinicalTrials.gov identiﬁer: NCT01595295.
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Open access under CC BY-NC-ND 1. Introduction
Therapy of CMML  still remains challenging and unsatisfactory.
So far no strategy has proven effective in prolonging overall survival
(OS). Allogeneic stem cell transplantation, the only curative option,
is only available to a small number of patients, and outcome still
remains unsatisfactory, with a disease-free survival of 18–20% at 5
years [1,2]. Until recently, best supportive care (BSC), aimed at ame-
liorating the symptoms and complications of bone marrow failure,
was the mainstay of treatment for CMML.  While low-dose cytara-
bine [3], topotocan [4], farensyltransferase inhibitors [5,6], and oral
etoposide [7] have been used in CMML,  hydroxyurea is usually the
license.
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Table 1
Comparison of full publications on CMML-patients treated with azacitidine.
Group Silverman [10] Fenaux [12] Costa [13] van der Helm [17] Ozbalak [15] Thorpe [16] Wong [18] Fianchi [14] Ades [19] Present study
Year  published 2002 2009 2011 2011 2012 2012 2012 2012 2013 2013
Country  USA France Pennsylvania Holland Turkey Portugal, Australia Australia Italy France, USA Austria
n 7 9 38 (36) 12 5 10 11 31 76 48
Inhabitants (million) 311.6 65.4 12.8 16.6 74.7 33.2 23.0 60.8 377.0 8.2
n  trt. with AZA/capita 0.02 0.14 2.81 0.72 0.07 0.30 0.48 0.51 0.20 5.85
Phase  III III Retrosp. Retrosp. Retrosp. Retrosp. Retrosp. Retrosp. Retrosp. Retrosp.
Median  age (years) (range) n.g. n.g. 70.5 65 (51–74) 74 (53–80) 66 (41–769 65 (42–80) 69 (53–84) 70 (33–85) 71 (38–87)
Female  (%) n.g. n.g. 19 50 40 20 n.g. 26 29 41
FAB-subtype (%)
MD-CMML (<13 G/l) 100 100 31 n.g. 80 60 64 65 57 42
MP-CMML (>13 G/l) 0 0 69 n.g. 20 40 36 35 43 58
WHO-subtype (%)
CMML-1 n.g. 9 73 n.g. 100 90 64 42 55 40
CMML-2  n.g. 91 27 n.g. 0 10 43 58 45 60
Secondary CMML (%) n.g. 0 8 n.g. n.g. 30 n.g. 16 n.g. 8
BM  blasts (%)
<10% n.g. 0 72 n.g. n.g. n.g. n.g. n.g. n.g. 60
10–19%  n.g. 100 25 n.g. n.g. n.g. n.g. n.g. n.g. 40
Unknown n.g. 0 3 n.g. n.g. n.g. n.g. n.g. n.g. 0
ECOG  > 2 (%) 0 0 n.g. n.g. 20 n.g. n.g. n.g. n.g. 23
Splenomegaly (%) n.g. n.g 28 n.g. n.g. 40 n.g. n.g. 30a 19b
IPSS cytogenetic risk (%)
Good n.g. n.g. 53 58 100 60 55 74 n.g. 73
Intermediate n.g. n.g. 36 42 0 20 18 19 n.g. 17
Poor  n.g. n.g. 8 0 0 20 18 3 n.g. 6
Not  evaluable/no data n.g. n.g. 3 0 0 0 9 3 n.g. 4
Prior  therapy (%)
None n.g. n.g. 44 58 n.g. 40 55 n.g. 53 50
HU  0 n.g. 31 25 n.g. 30 n.g. 35 17 31
G-CSF/ESA 0/allowed n.g. 8/11 0/0 n.g. 10/10 n.g. n.g. 12 0/8
Others  including CTX 0 n.g. 19 0 n.g. 20 n.g. n.g. 16 10
Azacitidine schedule (%)
d1–7 100 100 76 100 100d n.g. 91 90 n.g. 69
d1–5 0  0 24c 0 0 n.g.c 0 10 n.g. 10
5-2-2  0 0 0 0 0 0 0 0 n.g. 19
Others  0 0 0 0 0 0 9 0 n.g. 2
Median  cycles (range) n.g. n.g. 5 8 (1–15) 8.5 (8–15) 8 (4–29) 8 (2–29) 6 (2–31) 6 (1–40) 5.5 (1–65)
Median  follow-up (months) n.g. n.g. n.g. n.g. 23 12 15.9 n.g. 36 10
Median  OS (months) n.g. n.g. 12 n.g. n.g. 20 17.2 37 29 12.6
ORR  (%) (ITT) n.g. n.g. 39 50 60 60 55 51 43 54
CR/(m)  CR n.g. n.g. 11 33 20 40 36 45 25 13
PR  n.g. n.g. 3 0 20 0 9 3 1 6
HI  n.g. n.g. 25 17 20 20 9 6 17 35
SD  only n.g. n.g. 36 33 60 40 36 23 n.g. 8
ORR,  n/n (% ITT)
MD-CMML n.g. n.g. 6/11 (55) n.g. 2/4 (50) 3/4 (75) 5/7 (71) n.g. n.g. 7/20 (35)
MP-CMML n.g. n.g. 8/25 (32) n.g. 1/1 (100) 3/6 (50) 1/4 (25) n.g. n.g. 19/28 (68)
ORR,  n/n (% ITT)
CMML-1 n.g. n.g. 9/26 (35) n.g. 3/5 (60) 5/9 (56) 4/7 (57) n.g. n.g. 10/18 (56)
CMML-2 n.g. n.g. 5/9 (56) n.g. 0/0 (0) 1/1 (100) 2/4 (50) n.g. n.g. 15/29 (52)
Prognostic for OS in UVA
Splenomegaly n.g. n.g. n.g. n.g. n.g. n.g. n.g. n.g. Yes (p = 0.02) No (p = 0.435)b
WBC  >13 G/l n.g. n.g. Yes (p = 0.02) n.g. n.g. n.g. n.g. n.g. Yes (p = 0.039) No (p = 0.419)
BM-blasts >10%/CMML-1/-2 n.g. n.g. No (p = 0.3) n.g. n.g. n.g. n.g. n.g. Yes (p = 0.05) No (p = 0.636)
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treatment of choice for palliative cytoreduction. Although relevant
complete response (CR) rates have been observed with intensive
chemotherapy, remissions are typically short, even with continua-
tion of intensive post-remission therapy, and longterm disease-free
survival remains dismal [4,8,9].
While hypomethylating agents have been prospectively shown
to prolong OS in MDS-patients, randomized trials included only
7–14 CMML-patients which were not reported separately [10–12].
Approval of azacitidine in CMML  is thus based on limited experi-
ence and restricted to non-myeloproliferative disease. Decitabine
is not yet approved for the treatment of CMML  in Europe. Since
FDA-approval, several trials and retrospective reports with azac-
itidine have included small numbers of CMML  patients (Table 1)
[10,12–19].
Our aim was  to deﬁne the value of azacitidine in daily-life
patients with CMML  in both its myelodysplastic (MD-CMML) and
myeloproliferative form (MP-CMML). We  thus examined toxic-
ity, efﬁcacy, OS and the effect of putative prognostic parameters
on OS in 48 CMML-patients treated with azacitidine (ClinicalTri-
als.gov: NCT01595295). In the absence of clinical trials comparing
hypomethylating agents versus conventional treatment options,
it is unclear whether azacitidine can improve overall survival
in CMML.  We thus performed two  matched-pair analyses (i.e.
drawing on the data base of the Düsseldorf MDS Registry):: azaci-
tidine versus BSC (42 matched-pairs) and versus hydroxyurea (22
matched-pairs).
2. Methods
Registry design, patient eligibility, data collection and monitoring, assessment
of  efﬁcacy, safety and endpoints within the Austrian Azacitidine registry were per-
formed as previously described [20]. OS was  assessed using the Kaplan–Meier
method. Univariate analyses were performed with log-rank tests. Cox-regression
stratiﬁed on the various factors was  used for analyses of risk-factors for OS. Base-
line characteristics were compared by non-parametric tests (Chi-squared test for
qualitative variables, Wilcoxson test for quantitative variables). Survival rates at 1
and  2 years were compared using the z-test for proportions. Analyses were per-
formed with SAS and/or SPSS. The search-pool for matched-pairs comprised 516
CMML-patients: 426 CMML-patients from the Düsseldorf MDS Registry, and 90
CMML-patients from Austrian hematology centers. Matching was performed as
previously described [21]. The following characteristics were used for matching:
age (±5 years), gender, CMML-type according to WHO-classiﬁcation (CMML-1/2)
as  well as FAB-classiﬁcation (MD-/MP-CMML). In cases in which several poten-
tial  matched-pair partners were possible, the most appropriate partner was chosen
based on parity with IPSS cytogenetic risk category and/or score, LDH </≥225 mg/dl
and  spleen size. 42 BSC-matches and 22 hydroxyurea-matches were found. Main
difﬁculties were ﬁnding matches for young, female CMML-1 patients and for
MD-CMML  patients treated with hydroxyurea. These bottlenecks are compre-
hensible, since CMML  predominantly occurs in males, and young patients with
MD-CMML  are rarely treated with BSC or hydroxyurea only. Survival was mea-
sured from initial diagnosis for the matched-pair analysis with BSC, and from
onset of treatment with azacitidine or hydroxyurea for the matched-pair analy-
sis  with hydroxyurea. Treatment choice, time of treatment initiation, duration and
modiﬁcation were exclusively at the discretion of the respective treating physi-
cian.
3. Results
3.1. Patient characteristics
Between 02/2009 and 02/2013, 48 CMML-patients from 11 cen-
ters for hematology and oncology were included; no patients were
excluded from the analyses. Patient baseline characteristics are
shown in Table 2. Median age was 71 years (range 38–87), 60%
had CMML-2, 42% had MD-CMML, and 8% had treatment-related
CMML.  Splenomegaly at azacitidine treatment start was  present
in 48% of patients. According to the CMML-speciﬁc cytogenetic
score (CPSS) [22], 71%, 8% and 17% had a good, intermediate or
unfavorable karyotype, respectively (Table 2). Off-EMA-label use
of azacitidine occurred in 77% (i.e. patients with CMML-1 and/or
MP-CMML).
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Table 2
Baseline characteristics.
Median age (years) (range) 71 (38–87)
Gender male, n (%) 29 (60.4)
WHO-subtype, n (%)
CMML-1 19 (39.6)
CMML-2 29 (60.4)
CMML type, n (%)
De novo CMML  44 (91.7)
Treatment-related CMML 4 (8.3)
FAB-subtype, n (%)
MD-CMML  20 (41.7)
MP-CMML 28 (58.3)
Splenomegaly
Yes  23 (47.9)
≥17 < 20 cm 6 (12.5)
≥20  cm 3 (6.3)
No 23 (47.9)
Unknown 2 (4.2)
PB  blasts, n (%)
0% 15 (31.3)
>0% 33 (68.8)
BM  blasts, n (%)
<10% 29 (60.4)
10–19% 19 (39.6)
Cytopenias at diagnosis, n (%)
1 Cytopenia 16 (33.3)
2 Cytopenias 29 (60.4)
3 Cytopenias 3 (6.3)
Transfusion dependence (TD) prior to AZA, n (%)
Any type of TD 29 (60.4)
RBC-TD 24 (50.0)
PLT-TD 12 (25.0)
RBC-TD + PLT-TD 7 (14.6)
FAB-subtype and RBC-TD, n/n (%)
MD-CMML  10/20 (50.0)
MP-CMML 14/28 (50.0)
FAB-subtype and PLT-TD, n/n (%)
MD-CMML  5/20 (25.0)
MP-CMML 7/28 (25.0)
Serum-erythropoietin, n (%)
<50 IU/l 12 (25.0)
50–500 9 (18.8)
>500 0 (0.0)
Not evaluated 27 (56.3)
LDH, n (%)
<225 U/l 9 (19.2)
>225 U/l 35 (72.9)
Not evaluated 4 (8.5)
Ferritin, n (%)
<1000 g/l 16 (33.3)
≥1000 g/l 8 (17.0)
Not evaluated 24 (51.1)
Pre-treatment cytogenetics, n (%)a,b
Not evaluable/no data 2 (4.2)
Normal 33 (68.8)
Speciﬁc aberrations 13 (27.1)
+8,  −7 7 (14.6), 2 (4.2)
Others, complex 3 (6.3)
IPSS cytogenetic risk group, n (%)
Good 35 (72.9)
Intermediate 8 (16.7)
Poor 3 (6.3)
Not evaluable/no data 2 (4.2)
CMML cytogenetic risk group, n (%)
Low 30 (70.8)
Intermediate 4 (8.3)
High 8 (16.7)
Not evaluable/no data 2 (4.2)
Comorbidities, n (%)a
None 7 (14.6)
Thromboembolic episodes 1 (2.1)
Renal insufﬁciency 15 (31.3)
Liver disease 10 (20.8)
Diabetes mellitus 8 (16.7)
Coronary artery disease 11 (22.9)
COPD 7 (14.6)
Solid tumor 4 (8.3)
Hematologic neoplasia + MGUS 7 (14.6)
Table 2 (Continued)
Number of comorbidities, n (%)
0–1 15 (31.3)
2–3  19 (39.6)
>3  14 (29.2)
ECOG-PS, n (%)
ECOG <2 37 (77.1)
ECOG >2 11 (22.9)
HCT-CI, n (%)
Low risk 10 (20.8)
Int  risk 19 (39.6)
High risk 19 (39.6)
Treatment prior to azacitidine, n (%)a
None 26 (54.2)
Erythropoiesis stimulating agents (ESA) 4 (8.3)
Thrombopoiesis stimulating agents (TSA) 1 (2.1)
Iron chelation treatment (ICT) 4 (8.3)
Hydroxyurea (HU) 15 (31.3)
Chemotherapy (CTX) 2 (4.2)
Others 3 (6.3)
Reason for treatment, n (%)a
1st line treatment 26 (54.2)
Bridging to allogeneic-SCT 2 (4.2)
Maintenance after CR to chemotherapy 1 (2.1)
No CR to conventional chemotherapy/allogeneic-SCT 1 (2.1)
No CR/adequate disease control to other prior HU 15 (31.3)
No CR/adequate disease control to other drugs 4 (8.3)
MD,  myelodysplastic CMML  (i.e. CMML  with <13 G/l WBC); MP,  myeloprolifera-
tive (i.e. CMML with <13 G/l WBC); PB, peripheral blood; BM,  bone marrow; RBC,
red  blood cell; PLT, platelet; COPD, chronic obstructive pulmonary disease; MGUS,
monoclonal gammopathy of unknown signiﬁcance; ECOG-PS, European Coopera-
tive Group Prognostic Score; HCT-CI, Hematopoietic Stem Cell Comorbidity Index;
SCT, stem cell transplantation; CR, complete response.
a Numbers may  add up to >100% as multiple selections were possible.
b Pre-treatment cytogenetics were available in 94% of patients and were deter-
mined by conventional metaphase karyotyping, interphase-FISH, or both.
3.2. Treatment modalities
A total of 458 azacitidine cycles were applied to
all patients. Azacitidine was given 1st line (54%), after
hydroxyurea/chemotherapy-failure (33%), or after prior growth-
factors/iron-chelators/other substances (13%) (Table 2). The
median number of azacitidine cycles was 5.5 (range 1–65). Most
patients (88%) predominantly received 7 days of azacitidine
(69% FDA-approved d1–7, 19% 5-2-2) (Supplemental Table 1).
FDA-approved azacitidine target-dose (75 mg/m2 × 7 ± 10%) was
reached in 62% of applied cycles; 18% of all cycles were admin-
istered as ‘ﬂat’ dosage (i.e. 100 mg  azacitidine/cycle-day). Dose
reduction of azacitidine due to an adverse event was necessary in
17%.
3.3. Concomitant treatment and best supportive care measures
Erythropoietin stimulating agents (ESA) (9%), iron chelation
treatment (4%), and G-CSF (3%) were given in parallel to azacitidine
when deemed necessary by the treating physician. Nine patients,
ﬁve of which had already received hydroxyurea prior to azacitidine
treatment start, received hydroxyurea concomitantly.
3.4. Overall response to azacitidine
Overall response (deﬁned according to IWG  2006 criteria [23]
and including complete response (CR), marrow response (mCR),
partial response (PR) and/or hematologic improvement (HI)) was
documented in 54.2% of the intention-to-treat (ITT) cohort and
in 70.3% of patients evaluable according to IWG-criteria (i.e. had
received >2 cycles of azacitidine); Hematologic improvement was
documented in 50% (ITT) and 65% (IWG), respectively; CR/mCR was
achieved in 13% (ITT) and 26% (IWG) (Supplemental Table 2).
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Table 3
Speciﬁc adverse events.
Variable Grade n pts. (%) n total
events
Hematologic toxicitya G3–4 27 (56.3) 73
Thrombopenia G3–4 21 (43.8) 59
Neutropenia G3–4 10 (20.8) 12
Anemia G3–4 19 (39.6) 47
Bleeding events – 15 (31.3) 29
Febrile neutropenia – 6 (12.5) 7
Infectious
complications
G1–2 17 (35.4) 55
G3–4 8 (16.7) 11
Non-hematologic toxicity
Liver G1–2 0 (0.0) 0
G3–4 0 (0.0) 0
Kidney G1–2 4 (8.3) 5
G3–4 0 (0.0) 0
Heartb G1–2 2 (4.2) 3
G3–4 8 (16.7) 14
Blood pressure G1–2 0 (0.0) 0
G3–4 0 (0.0) 0
Metabolic G1–2 2 (4.2) 2
G3–4 0 (0.0) 0
Thromboembolic G1–2 2 (4.2) 2
G3–4 1 (2.1) 1
Neurologic G1–2 6 (12.5) 10
G3–4 1 (2.1) 1
Nausea G1–2 4 (8.3) 4
G3–4 0 (0.0) 0
Vomiting G1–2 1 (2.1) 1
G3–4 0 (0.0) 0
Constipation G1–2 3 (6.3) 5
G3–4 0 (0.0) 0
Diarrhea G1–2 6 (12.5) 9
G3–4 0 (0.0) 0
GIT-others G1–2 5 (10.4) 5
G3–4 0 (0.0) 0
Injection site
reaction
G1–2 9 (18.8) 12
G3–4 5 (10.4) 8
Fatigue Relieved by rest 6 (12.5) 7
Not relieved by rest 8 (16.7) 11
Limiting self care 1 (2.1) 1
Pain Mild 9 (18.8) 18
Moderate 7 (14.6) 11
Severe 0 (0.0) 0
Surgery Elective 3 (6.3) 4
Emergency 3 (6.3) 3
Fall Total 8 (16.7) 10
With fracture 1 (2.1) 1
With hemorrhage 2 (4.2) 2
Novel solid tumor Yes 0 (0.0) 0
Pts., patients; GIT, gastrointestinal.
a Grade 3–4 cytopenias reported, are those that were documented as adverse
events, and thus felt to be a worsening of pre-existing cytopenia by the respective
treating physicians.
b Reported cardiac AE were: left-ventricular output failure (n = 12 events in 6L. Pleyer et al. / Leukemia
Response to azacitidine did not correlate with the schedule
pplied (i.e. 5 or 7 days), or azacitidine dose/cycle (Supplemen-
al Table 3). The median number of cycles received by responding
atients was 10.5 (range 3–65), as compared to 2.5 (range 1–18)
or non-responders.
Overall response rate was not lower for patient populations for
hom azacitidine has not been approved by EMA  in Europe yet:
7% for CMML-1 and 83% for MP-CMML  (Supplemental Table 2).
.5. Time to best response and response deepening
Median time to ﬁrst response was 4.0 months. First response
ccurred at cycle 3, 4 and 5 in 42%, 77% and 92% of responding
atients, respectively. First response was best response in 81%
f responding patients. Further deepening of response after ﬁrst
esponse (i.e. marrow response occurring after HI) was  seen in 19%
f responders. Median time from ﬁrst to best response was  3.5
onths.
.6. Toxicity and adverse events
A total of 195 adverse events (AE) were documented in 456
zacitidine cycles. The number of AE was highest in cycles one
nd two. Overall, 29% of all AE and 33% of grade 3–4 (G3–4) AE
ere attributed to azacitidine; 22% resulted in hospitalization, 5%
esulted in death; 68% had no consequence for azacitidine treat-
ent. AE resulted in azacitidine treatment pause, dose reduction,
rolongation of azacitidine cycle duration >28 days, or termina-
ion of treatment in 17%, 6%, 3% and 8%, respectively (Supplemental
able 4).
G3–4 hematologic toxicity occurred in 56% (Table 3). Clinically
elevant bleeding events were noted in 31%. G3–4 infectious events
ccurred in 17% and were dominated by pulmonary infections,
SV- and CMV-reactivations.
Non-hematologic G3–4 events mostly occurred as injection site
eactions (10%) and in the cardiac system (21%) (Table 3). In 70% of
atients experiencing cardiac G3–4 events, pre-existing coronary
rtery disease (n = 4), arrhythmias (n = 5) and/or valvular heart dis-
ase (n = 3) were documented prior to azacitidine treatment and
orsening was not thought to be azacitidine-related.
.7. Overall survival and evaluation of potential prognostic
arameters
At the time of data cut-off (11.03.2013), 34 patients were dead,
ight were alive and still on azacitidine, and six were alive, but
reatment with azacitidine was terminated. No patients were lost
o follow-up. Median follow-up was 9.8 months.
Median OS was 31.2 (95% CI 26.1–36.6) months as of ﬁrst diag-
osis, and 12.6 (95% CI 6.3–18.9) months as of treatment start
ith azacitidine. Median time from initial diagnosis to initiation of
zacitidine was 0.9 months for untreated (n = 26), 14.7 months for
retreated (n = 22) and 7.4 months for the total cohort, respectively.
ermination of azacitidine treatment in the eleven patients that
eceived ≤2 cycles was  death (n = 6), disease progression (n = 3),
oxicity (n = 1) and patient’s wish (n = 1), respectively. Median time
rom azacitidine treatment stop to death was 2.1 months.
Median OS as of azacitidine treatment start in responding
atients was 19.4 (95% CI 7.9–17.4; range 2.2–68.2) months. Pro-
ression free survival (PFS) in responding patients was  12.6 (95% CI
3.1–28.8; range −1.5–68.2) months. Progression deﬁning events
ere death due to any reason (n = 10), disease relapse/progression
fter HI (n = 7), new transfusion dependence (n = 2), transformation
o AML  (n = 2), allogeneic stem cell transplantation (n = 1), and no
vent/still on AZA at cut-off date (n = 4), respectively.patients), arrhythmia (n = 2), cardiac ischemia (n = 3), sudden cardiac death (n = 1),
and valvular insufﬁciency (n = 1).
In univariate analysis the following baseline parameters had a
signiﬁcant adverse effect on overall survival: pretreatment with
hydroxyurea (p = 0.011), monocyte count >5000/l  (p = 0.029), and
adverse cytogenetics (−7, −7q, abn(3q), or complex karyotype)
(p = 0.027). Addition of trisomy 8 as adverse cytogenetic marker
(as deﬁned by the CMML-speciﬁc cytogenetic risk group [22]) did
not add impact, but rather resulted in loss of statistical signiﬁcance
(Fig. 1 and Supplemental Table 3).
Female gender had a trend for an effect on OS (p = 0.055, Sup-
plemental Table 3). A trend for worse OS was seen in patients with
red blood cell transfusion dependence (RBC-TD) prior to azacitidine
treatment start (p = 0.068).Baseline factors that did not signiﬁcantly affect OS  included
age </≥75, WHO-type, FAB-type, bone marrow blast count
<10%/10–20%, spleen size </≥17 cm,  peripheral blood blasts,
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fig. 1. Forrest plot of factors signiﬁcantly affecting overall survival of azacitidine trea
BC-TI, red blood cell transfusion independence; IWG, International Working Grou
7q,  −7 and/or complex karyotype.
eutrophil count </≥2000/l, lymphocyte count </≥2000/l,
latelet-TD, S-EPO level, prior treatment with ESA or with ESA/G-
SF/iron chelators, LDH ≤/>225 IU/l, ECOG-PS, HCT-CI and the
bsolute number of comorbidities. Neither the IPSS cytogenetic
isk score, nor grouping according to the IPSS, R-IPSS, R-IPSS-age,
PSS, APSS or the CPSS risk scoring systems could prognosti-
ate OS (Supplemental Table 3). No signiﬁcant effect on OS could
e detected for achievement of FDA-approved azacitidine dose or
chedule, or treatment on/off-label according to EMA-label. Con-
omitant hydroxyurea had no inﬂuence on OS (Supplemental Table
).
The following response related factors had a signiﬁcant effect
n overall survival: achievement of RBC transfusion independence
RBC-TI) (p = 0.015), hematologic improvement (p < 0.001), mar-
ow response (p = 0.025), and overall response (p < 0.0001) (Fig. 1).
esponders had signiﬁcantly longer OS than non-responders (19.4
s. 5.6 months, p < 0.001), irrespective of CMML-subgroup accord-
ng to WHO- or FAB-classiﬁcation, or whether patients were treated
ff-label according to EMA  (Supplemental Table 5). Continued
zacitidine beyond ﬁrst response resulted in further deepening of
esponse in 19% of responders. This translated into signiﬁcantly
onger OS, compared with patients for whom ﬁrst response was
est response (32.8 vs. 17.0 months, p < 0.001) (Fig. 1).
The only adverse event and toxicity-related factor that had a sig-
iﬁcant negative effect on OS was non-hematologic toxicity G3–4
p = 0.007) (Fig. 1). It made no difference whether occurring G3–4
dverse events were attributable to azacitidine or not (Supplemen-
al Table 3).
.8. Matched-pair analyses reveal modest effects of azacitidine
n survival in CMML
Patient characteristics of parameters used for pairing of matches
or all cohorts can be taken from Supplemental Table 6. Median
S of azacitidine vs. BSC was 31.2 vs. 17.0 months, respectively
p = 0.251) (Supplemental Figure 1A). No statistically signiﬁcant
ifference in OS could be found in any of the subgroup-analyses
azacitidine 1st-line, azacitidine after hydroxyurea/chemotherapy-
ailure, MD-CMML, MP-CMML, treatment on/off-EMA-label).ML-patients (n = 48) in univariate analyses. HI indicates hematologic improvement;
eria; ITT, intent to treat population; Adverse karyotype was  deﬁned as presence of
However, OS was consistently longer and OS-differences of plus
7.8–18.0 months for the azacitidine-treated cohorts as compared
to the BSC-cohorts were observed (Supplemental Figure 1B and C
and Supplemental Table 7). In addition, a trend for higher two-year-
survival was  observed for the total azacitidine vs. BSC cohort (62%
vs. 41%, p = 0.067), as well as for the myelodysplastic subgroup (79%
vs. 54%, p = 0.085) and CMML-patients treated off-EMA-label (60%
vs. 38%, p = 0.099) (Supplemental Table 7).
Matched-pair analysis of azacitidine vs. hydroxyurea revealed
no difference in median OS as of treatment start (7.5 vs. 6.2 months
(p = 0.251); Supplemental Figure 1D, and Supplemental Table 7)
or as of initial diagnosis (18.3 vs. 17.0 months (p = 0.722); Supple-
mental Figure 2). However, comparison of azacitidine 1st-line vs.
hydroxyurea 1st-line revealed a trend for longer OS as of treat-
ment start in the azacitidine-cohort despite small sample sizes
(median OS 27.7 vs. 6.2 months, p = 0.072) (Fig. 2 and Supplemental
Table 7).
4. Discussion
In the absence of clinical trials performed exclusively in CMML-
patients, it is currently unclear whether azacitidine can improve
OS in CMML.  We here report on 48 Austrian CMML-patients who
were treated with azacitidine and were collected in the recently
established Austrian Azacitidine Registry.
The overall response rate (ITT) observed in the present study
(54%) is similar to that documented in previous reports (39–60%).
However, median OS was relatively low in our patients (12.6
months), which may  be due to the large number of pretreated
patients (46%). Responders had a median OS of 19.4 months and
a median PFS of 12.6 months. Short PFS is likely due to a high
rate of deaths not considered to be disease- or treatment-related
(70% of PFS deﬁning death events): cardiac failure (5/10 of death
events), renal failure, cerebral hemorrhage, and fall with fracture
and ensuing death. In addition, 8/26 responders had hematologic
improvement in one cell lineage only. Five of these had a response
in the white blood cell compartment only, reﬂecting palliative
cytoreduction, and all of these had very short PFS (range 2.2–8.7
months).
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Cig. 2. Kaplan–Meier curve of matched-pair analysis: Azacitidine 1st line vs. hydro
onths for the hydroxyurea treated cohort (p = 0.072).
Our results suggest that some CMML-patients may  beneﬁt
rom azacitidine treatment, irrespective of the WHO- or FAB-
lassiﬁcation, and irrespective of whether they were treated
ccording to EMA-label for azacitidine or not (Supplemental Tables
 and 5). Others have also shown relevant responses to azaciti-
ine in non-EMA-indication cohorts (Table 1). Not surprisingly,
esponders always had longer OS than non-responders Therefore,
n our opinion, MP-CMML  and/or CMML-1 patients requiring treat-
ent, i.e. constitutive symptoms due to hyperproliferation and/or
plenomegaly and/or transfusion dependence, should not be pre-
luded from treatment with azacitidine.
Baseline markers that predict response to azacitidine would be
esirable, as non-responding patients may  fare identically with
SC and/or palliative hydroxyurea treatment only. The knowledge
n predictive baseline markers for hypomethylating agents is at
est descriptive for CMML-patients treated with azacitidine, and
onﬂicting results exist for most variables, which is likely due to
mall patient numbers (Table 1). We  analyzed a number of risk
actors known to be relevant in CMML  (Table 1 and Supplemental
able 3). In these analyses, we show that treatment with hydrox-
urea prior to azacitidine may  adversely affect OS (median OS 7.9
s. 16.9 months, p = 0.011). Similarly, Ades et al. showed a trend
p = 0.07) for worse OS for patients pre-treated with either hydrox-
urea (n = 13) or chemotherapy (n = 12), but did not report on the
ffect of pretreatment with hydroxyurea alone [19]. Comparing our
esults with those of fully published CMML-cohorts treated with
zacitidine, it seems as if elevated monocyte count is the only base-
ine variable which consistently adversely affected OS, IPSS-score,
LT-count, and azacitidine dose do not seem to affect OS, whereas
onﬂicting results exist for all other parameters examined (Table 1)
10,12–19].
In the past, CMML  patients were often risk assessed with
rognostic scoring systems developed for MDS, i.e. the IPSS
24]. Several prognostic scores have been developed for CMML
22,24–29]. However, currently there is no agreement on progno-
tic factors or a prognostic score for CMML  [30]. We  analyzed IPSS,
-IPSS, R-IPSS-age, WPSS, APSS and CPSS, none of which could suf-
ciently separate survival curves in our large cohort of azacitidine
reated CMML-patients (Supplemental Table 3). Our data therefore
onﬁrm the ongoing need for an adequate risk-assessment tool in
MML,  the absence of which, likely reﬂects the immense tumor
eterogeneity and multiple molecular abnormalities observed in
MML  [30,31]. Recent insights indicate mutations in TET2 and 1st-line. Median overall survival was 27.7 in the azacitidine treated cohort vs. 6.2
ASXL1 genes, -both of which occur frequently in CMML-, as initial
driver mutations thought to play a relevant role in the etiopatho-
genesis of the disease [32]. Conﬂicting data exist as to whether
the incorporation of ASXL1 and/or TET2 mutation status improves
the prediction of outcome compared with scores based on clinical
parameters only [33,34].
In our CMML-cohort neither response to azacitidine, nor overall
survival correlated with achievement of the FDA-approved target
dose, the cumulative dose received per cycle, or the predominantly
applied schedule, similar to our observations in AML  [20]. Others
[14] have found similar results, corroborating the impression of
non-inferiority of alternative schedules and dosages demonstrated
by our data.
Special emphasis was  placed on documentation of adverse
events in quality and quantity similar to that of clinical trials.
We present here, the ﬁrst comprehensive toxicity and adverse
events evaluation for azacitidine treated CMML-patients (Table 3).
Importantly, occurrence of AE per se, as well as dose reductions of
azacitidine resulting there from, did not negatively impact OS (Sup-
plemental Table 3). Rare cases of non-hematologic G3–4 events,
occurring mainly in the cardiac system in patients with preexisting
cardiac disease, were the only AE to adversely affect OS (Fig. 1).
We  recently reported similar safety results for 155 AML-patients
[20]. In our opinion, the occurrence of AE should not lead to per-
manent treatment discontinuation in most cases, and azacitidine
treatment should be continued as planned whenever possible, if
necessary with dose reduction and/or treatment pause.
This represents the ﬁrst matched-pair analysis of azacitidine
treated CMML-patients. In the comparison of azacitidine vs. BSC
median OS was consistently longer and survival differences of up
to 21.5 months were observed (Supplemental Figure 1A–C and Sup-
plemental Table 6). Kaplan–Meier curves separated nicely initially
but converged at ∼50 months (Supplemental Figure 1A and B).
Trends for higher two-year-survival were observed for the total
azacitidine vs. BSC cohort (62% vs. 41%, p = 0.067), the myelodys-
plastic subgroup (79% vs. 54%, p = 0.085), and the off-EMA-label
subgroup (60% vs. 38%, p = 0.099). Although statistical signiﬁcance
was not reached, these results may  be clinically relevant.
We also performed a matched-pair analysis of azacitidine-
treated patients with hydroxyurea-treated patients. We  chose
hydroxyurea as treatment comparator as the only phase-III trial
performed exclusively in CMML-patients (performed 17 years ago)
demonstrated superiority of hydroxyurea (n = 53) over etoposid
4  Resea
(
f
a
1
a
s
v
h
a
r
m
o
w
t
a
w
b
f
d
(
w
m
e
c
b
i
t
o
m
a
1
o
a
w
i
i
R
t
r
F
g
i
C
N
M
g
O
N
c
M
E
t
B
P
A
C
[
[
[82 L. Pleyer et al. / Leukemia
n = 52) [35]. In our matched-pair analysis, median OS differences
or azacitidine vs. hydroxyurea were low (7.5 vs. 6.2 months)
nd did not reach statistical signiﬁcance (Supplemental Figure
D). Fifteen patients were pretreated with hydroxyurea prior to
zacitidine, and this was a negative predictor of OS for patients
ubsequently treated with azacitidine (p = 0.011, median OS 7.9
s. 16.9 months) (Fig. 1). We  thus analyzed treatment-naive and
ydroxyurea/chemotherapy-pretreated matched-pair cohorts sep-
rately. Comparison of azacitidine 1st-line vs. hydroxyurea 1st-line
evealed a trend for longer OS in the azacitidine-cohort (p = 0.072,
edian OS 27.7 vs. 6.2 months) (Fig. 2 and Supplemental Table 6). In
rder to improve the impact of our ﬁndings, larger patient numbers
ill be required to be able to draw deﬁnite conclusions. However,
he rarity of the disease, the widespread use of azacitidine in CMML,
s well as the lack of other approved substances in this indication
ill be limiting factors in reaching sufﬁciently large patient num-
ers. In this regard, an international randomized trial comparing
ront-line azacitidine with frontline hydroxyurea would be highly
esirable (especially in MP-CMML). Pulsed high-dose hydroxyurea
2–3 g every 8 h for 48 h at intervals of 1–4 weeks) as comparator
ould be an interesting concept [36–38].
Our 48 patient datasets represent a larger number of cases than
ost existing published clinical trial data. This report reinforces
xisting evidence that azacitidine can be safely applied, is efﬁca-
ious, and may  be a new forthcoming standard of treatment in
oth myelodysplastic and myeloproliferative CMML.  Bearing the
nherent limitations of data generated from registries, as well as
he (in statistical terms) rather small patient number in mind,
ur observations of trends for survival differences of up to 21.5
onths seem encouraging, and we cautiously hypothesize, that
zacitidine may  result in longer OS of CMML-patients when used as
st-line treatment. CMML-patients refractory to hydroxyurea and
r chemotherapy do not seem to proﬁt from azacitidine therapy
nd may  fare identically with BSC and/or palliative cytoreduction
ith hydroxyurea. A large randomized trial is urgently needed to
dentify in which conditions hypomethylating agents may  be useful
n CMML.
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